Last reviewed · How we verify
lixisenatide + glargine
Lixisenatide stimulates insulin secretion via GLP-1 receptor agonism, while glargine provides basal insulin coverage, together improving glycemic control in type 2 diabetes.
Lixisenatide stimulates insulin secretion via GLP-1 receptor agonism, while glargine provides basal insulin coverage, together improving glycemic control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | lixisenatide + glargine |
|---|---|
| Also known as | GLP-1 plus basal insulin |
| Sponsor | Medical University of Warsaw |
| Drug class | GLP-1 receptor agonist + basal insulin |
| Target | GLP-1 receptor; insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Lixisenatide is a GLP-1 receptor agonist that enhances postprandial insulin secretion in response to glucose, slows gastric emptying, and reduces glucagon secretion. Insulin glargine is a long-acting basal insulin that provides steady background insulin levels. The combination addresses both fasting and postprandial hyperglycemia in type 2 diabetes patients.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Hypoglycemia
- Vomiting
- Diarrhea
- Headache
Key clinical trials
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus (PHASE4)
- Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents (PHASE4)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes (PHASE4)
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |